摘要
目的分析予以妊娠期糖尿病(GDM)患者门冬胰岛素治疗对其血糖稳定性的影响效果。方法选取2019年2月—2021年11月在该院接受治疗的52例GDM患者为研究对象,依据随机数表分为对照组(26例,生物合成人胰岛素治疗)和观察组(26例,门冬胰岛素治疗),对比两组患者血糖控制情况、分娩结局及母婴不良结局发生率。结果治疗1、5、7 d后,观察组三餐后2 hPG水平为(7.35±1.59)、(7.15±1.62)、(7.05±1.02)、(6.70±0.66)、(6.12±1.03)、(6.28±1.06)、(6.20±0.21)、(6.58±0.35)、(6.12±0.35)mmol/L,低于对照组的(8.36±1.62)、(8.22±1.66)、(7.82±1.13)、(7.58±0.96)、(6.92±1.54)、(7.12±1.06)、(6.48±0.32)、(7.15±0.64)、(6.56±0.44)mmol/L,差异有统计学意义(t=2.269、2.352、2.579、3.852、2.202、2.898、3.730、3.984、3.990,P<0.05);观察组FPG水平与对照组对比,差异无统计学意义(t=0.230、0.179、0.708,P>0.05)。两组血糖达标时间、早餐前血糖水平对比,差异无统计学意义(t=0.868、0.281,P>0.05)。观察组自然分娩率及母婴不良结局发生率分别为65.38%、11.54%,对照组分别为73.08%、15.40%,两组对比差异无统计学意义(χ^(2)=0.361、0.000,P>0.05)。结论予以GDM患者门冬胰岛素治疗较生物合成人胰岛素能够更好地稳定患者餐后血糖水平,为其提供更为有利的治疗。
Objective To analyze the effect of insulin aspart on blood glucose stability in patients with gestational diabetes mellitus(GDM).Methods 52 GDM patients who were treated in the hospital from February 2019 to November 2021 were selected as the research subjects.According to the random number table,they were divided into control group(26 cases,treated with biosynthetic human insulin)and observation group(26 cases,treated with insulin aspart).The blood glucose control,delivery outcomes and incidence of adverse maternal and infant outcomes were compared between the two groups.Results After 1 d,5 d and 7 d of treatment in the observation group,the 2 hPG levels after three meals were(7.35±1.59)mmol/L,(7.15±1.62)mmol/L,(7.05±1.02)mmol/L,(6.70±0.66)mmol/L,(6.12±1.03)mmol/L,(6.28±1.06)mmol/L,(6.20±0.21)mmol/L,(6.58±0.35)mmol/L,(6.12±0.35)mmol/L,which were lower than the control group(8.36±1.62)mmol/L,(8.22±1.66)mmol/L,(7.82±1.13)mmol/L,(7.58±0.96)mmol/L,(6.92±1.54)mmol/L,(7.12±1.06)mmol/L,(6.48±0.32)mmol/L,(7.15±0.64)mmol/L,(6.56±0.44)mmol/L,and the difference was statistically significant(t=2.269,2.352,2.579,3.852,2.202,2.898,3.730,3.984,3.990,P<0.05);there was no statistically significant difference in FPG level between the observation group and the control group(t=0.230,0.179,0.708,P>0.05).There was no statistically significant difference between the two groups in terms of the time when the blood glucose reached the standard and the blood glucose level before breakfast(t=0.868,0.281,P>0.05).The natural delivery rate and the incidence of adverse maternal and infant outcomes in the observation group were 65.38%and 11.54%,the control group was 73.08%and 15.40%,and there was no statistically significant difference between the two groups(χ^(2)=0.361,0.000,P>0.05).Conclusion Compared with biosynthetic human insulin,insulin aspart can better stabilize the postprandial blood glucose level of patients with GDM and provide more favorable treatment.
作者
冯锦秋
FENG Jinqiu(Department of Obstetrics and Gynecology,Pizhou Hospital of Traditional Chinese Medicine,Pizhou,Jiangsu Province,221300 China)
出处
《糖尿病新世界》
2022年第10期79-82,共4页
Diabetes New World Magazine
关键词
妊娠期糖尿病
门冬胰岛素
血糖稳定性
分娩结局
Gestational diabetes mellitus
Insulin aspart
Blood glucose stability
Delivery outcome